Clinical Trial

Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours

Recruiting
View on ClinicalTrials.gov →
Summary
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-30; most recent amendment 2026-01-23.
Trial Details
NCT Number NCT06397963
Lead Sponsor Grit Biotechnology
Collaborators: The Affiliated Hospital of Xuzhou Medical University, Beijing GoBroad Hospital, Beijing Arion Cancer Center
Conditions Solid Tumor, Adult
Enrollment 18 participants
Start Date 2024-04-18
Primary Completion 2027-04-18 (estimated)
Study Completion 2027-04-18 (estimated)
Updated on ClinicalTrials.gov 2026-01-26